Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

GlobalData, January 2012, Pages: 71

Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. The report identifies the key trends shaping and driving the global Ankylosing Spondylitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ankylosing Spondylitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Ankylosing Spondylitis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Ankylosing Spondylitis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Ankylosing Spondylitis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Ankylosing Spondylitis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Ankylosing Spondylitis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Ankylosing Spondylitis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Ankylosing Spondylitis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Ankylosing Spondylitis Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Ankylosing Spondylitis Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.2.1 Prevalence
2.2.2 Ethnicity
2.2.3 Gender
2.2.4 Quality of Life Parameters
2.2.5 Socioeconomic Impact
2.2.6 Mortality and Morbidity
2.3 Etiology and Pathology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 Patient History
2.5.2 Physical Examination
2.5.3 Laboratory Tests
2.5.4 Imaging Tests
2.5.5 Modified New York Criteria
2.6 Treatment and Management Options
2.6.1 Medications
2.6.2 Exercise and Physiotherapy
2.6.3 Surgery
2.7 Referral Pathway
2.8 GlobalData Pipeline Report Guidance
3 Ankylosing Spondylitis Therapeutics - Market Characterization
3.1 Overview
3.2 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Global
3.3 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Global
3.4 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - The US
3.5 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - The US
3.6 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - France
3.7 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - France
3.8 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Germany
3.9 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Germany
3.10 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Italy
3.11 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Italy
3.12 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Spain
3.13 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Spain
3.14 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - The UK
3.15 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - The UK
3.16 Ankylosing Spondylitis Therapeutics Market Size (2006-2011) - Japan
3.17 Ankylosing Spondylitis Therapeutics Market Forecast (2011-2019) - Japan
3.18 Drivers and Barriers for the Ankylosing Spondylitis Therapeutics Market
3.18.1 Drivers for the Ankylosing Spondylitis Therapeutics Market
3.18.2 Barriers for the Ankylosing Spondylitis Therapeutics Market
3.19 Opportunity and Unmet Need Analysis
3.20 Key Takeaway
4 Ankylosing Spondylitis Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the Ankylosing Spondylitis Market
4.3.1 Celebrex (celecoxib)
4.3.2 Arcoxia (etoricoxib)
4.3.3 Enbrel (etanercept)
4.3.4 Humira (adalimumab)
4.3.5 Remicade (infliximab)
4.3.6 Simponi (golimumab)
4.4 Key Takeaway
5 Ankylosing Spondylitis Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Ankylosing Spondylitis Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 Ankylosing Spondylitis Therapeutics - Phase III Pipeline
5.3.2 Ankylosing Spondylitis Therapeutics - Phase II Pipeline
5.3.3 Ankylosing Spondylitis Therapeutics - Phase I Pipeline
5.3.4 Ankylosing Spondylitis Market - Pre-Clinical Pipeline
5.4 Ankylosing Spondylitis Therapeutics Market - Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Ankylosing Spondylitis Therapeutics - Promising Drugs Under Development
5.7 Molecule Profile for Promising Drugs under Development
5.7.1 AIN457 (secukinumab)
5.7.2 Cimzia (certolizumab pegol)
5.8 Key Takeaway
6 Ankylosing Spondylitis Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (the US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Ankylosing Spondylitis Therapeutics Clinical Trials
7 Ankylosing Spondylitis Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Ankylosing Spondylitis Therapeutics: Implications for Future Market Competition
8 Ankylosing Spondylitis Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Novartis
8.2.2 UCB
9 Licensing and Partnership Deals
10 Ankylosing Spondylitis Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Prevalence of Ankylosing Spondylitis in Different Ethnic Groups and Regions
Table 2: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2006-2011
Table 3: Ankylosing Spondylitis Therapeutics Market, Global, Forecast ($m), 2011-2019
Table 4: Ankylosing Spondylitis Therapeutics Market, The US, Revenue ($m), 2006-2011
Table 5: Ankylosing Spondylitis Therapeutics Market, The US, Forecast ($m), 2011-2019
Table 6: Ankylosing Spondylitis Therapeutics Market, France, Revenue ($m), 2006-2011
Table 7: Ankylosing Spondylitis Therapeutics Market, France, Forecast ($m), 2011-2019
Table 8: Ankylosing Spondylitis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Table 9: Ankylosing Spondylitis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Table 10: Ankylosing Spondylitis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Table 11: Ankylosing Spondylitis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Table 12: Ankylosing Spondylitis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Table 13: Ankylosing Spondylitis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Table 14: Ankylosing Spondylitis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Table 15: Ankylosing Spondylitis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Table 16: Ankylosing Spondylitis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Table 17: Ankylosing Spondylitis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Table 18: Components of Ankylosing Spondylitis Disease Activity
Table 19: Components of Ankylosing Spondylitis Disease Activity
Table 20: Components of Ankylosing Spondylitis Disease Activity
Table 21: Proportion of ASAS Responders at Weeks 14 and 24
Table 22: Median Percent Improvement in ASAS Components AT Week 14
Table 23: Ankylosing Spondylitis Therapeutics, Phase III Pipeline, 2011
Table 24: Ankylosing Spondylitis Therapeutics, Phase II Pipeline, 2011
Table 25: Ankylosing Spondylitis Therapeutics, Phase I Pipeline, 2011
Table 26: Ankylosing Spondylitis Therapeutics, Pre-Clinical Pipeline, 2011
Table 27: Ankylosing Spondylitis Therapeutics - Most Promising Drugs Under Development, 2011
Table 28: Ankylosing Spondylitis Therapeutics, Clinical Trials by Country, 2011
Table 29: Ankylosing Spondylitis Therapeutics, Clinical Trials by Phase, 2011
Table 30: Ankylosing Spondylitis Therapeutics, Clinical Trials by Status of Development, 2011
Table 31: Ankylosing Spondylitis Therapeutics, Prominent Sponsors, 2011
Table 32: Ankylosing Spondylitis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 33: Novartis - Inflammation and Immunology Pipeline, 2011
Table 34: Novartis - Ankylosing Spondylitis Pipeline, 2011
Table 35: UCB - Immunology Pipeline, 2011
Table 36: UCB- Ankylosing Spondylitis Pipeline, 2011
Table 37: Ankylosing Spondylitis Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures
Figure 1: Ankylosing Spondylitis
Figure 2: Pathogenesis of Ankylosing Spondylitis
Figure 3: Modified New York Criteria
Figure 4: Comparisons of NSAIDs
Figure 5: Comparisons of DMARDs
Figure 6: Comparisons of Corticosteroids
Figure 7: Comparisons of Biologics
Figure 8: Ankylosing Spondylitis Therapeutics - Referral Pathway
Figure 9: Ankylosing Spondylitis Therapeutics Market, Global, Revenue ($m), 2006-2011
Figure 10: Ankylosing Spondylitis Therapeutics Market, Global, Forecast ($m), 2011-2019
Figure 11: Ankylosing Spondylitis Therapeutics Market, The US, Revenue ($m), 2006-2011
Figure 12: Ankylosing Spondylitis Therapeutics Market, The US, Forecast ($m), 2011-2019
Figure 13: Ankylosing Spondylitis Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 14: Ankylosing Spondylitis Therapeutics Market, France, Forecast ($m), 2011-2019
Figure 15: Ankylosing Spondylitis Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 16: Ankylosing Spondylitis Therapeutics Market, Germany, Forecast ($m), 2011-2019
Figure 17: Ankylosing Spondylitis Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 18: Ankylosing Spondylitis Therapeutics Market, Italy, Forecast ($m), 2011-2019
Figure 19: Ankylosing Spondylitis Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 20: Ankylosing Spondylitis Therapeutics Market, Spain, Forecast ($m), 2011-2019
Figure 21: Ankylosing Spondylitis Therapeutics Market, The UK, Revenue ($m), 2006-2011
Figure 22: Ankylosing Spondylitis Therapeutics Market, The UK, Forecast ($m), 2011-2019
Figure 23: Ankylosing Spondylitis Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 24: Ankylosing Spondylitis Therapeutics Market, Japan, Forecast ($m), 2011-2019
Figure 25: Opportunity and Unmet Need in the Ankylosing Spondylitis Therapeutics Market, 2011
Figure 26: Ankylosing Spondylitis Therapeutics, Strategic Competitor Assessment, 2011
Figure 27: Ankylosing Spondylitis Therapeutics - Pipeline by Phase of Development, 2011
Figure 28: Ankylosing Spondylitis Therapeutics, Pipeline by Mechanism of Action (%), 2011
Figure 29: Ankylosing Spondylitis Therapeutics, Technology Trends Analytics Framework, 2011
Figure 30: Ankylosing Spondylitis Therapeutics, Technology Trends Analytics Framework, Description, 2011
Figure 31: Ankylosing Spondylitis Therapeutics, Clinical Trials by Country, 2011
Figure 32: Ankylosing Spondylitis Therapeutics, Clinical Trials by Phase (%), 2011
Figure 33: Ankylosing Spondylitis Therapeutics, Clinical Trials by Status of Development (%), 2011
Figure 34: Ankylosing Spondylitis Therapeutics, Overall Sponsors (%), 2011
Figure 35: Ankylosing Spondylitis Therapeutics, Prominent Sponsors (%), 2011
Figure 36: Ankylosing Spondylitis Therapeutics, Top Companies Participating in Clinical Trials, 2011
Figure 37: Ankylosing Spondylitis Therapeutics Market, Drivers and Restraints, 2011
Figure 38: Implications for Future Market Competition in the Ankylosing Spondylitis Market, 2011
Figure 39: Ankylosing Spondylitis Therapeutics Market, Pipeline by Company, 2011
Figure 40: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. The report identifies the key trends shaping and driving the global Ankylosing Spondylitis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Ankylosing Spondylitis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Ankylosing Spondylitis Therapeutics Market is Forecast to Show Moderate Growth until 2019

GlobalData estimates that the global ankylosing spondylitis therapeutics market had a value of $1,112m in 2011, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 5.1% over the next eight years to reach $1,650m by 2019. The market will witness several patent expiries of drugs including NSAIDs such as Celebrex (celecoxib) (2014 in the US and Europe) and biologics such as Enbrel (etanercept) (2012 in the US, and 2015 in Europe), Remicade (infliximab) (2014 in the US and Europe), and Humira (adalimumab) (2016 in the US and 2018 in Europe). In addition to this, the prevalence of ankylosing spondylitis is expected to remain stable over the forecast period. However, pipeline molecules such as AIN457 (secukinumab) and Cimzia (certolizumab pegol) are expected to launch in 2015. GlobalData expects these factors to account for moderate growth within the ankylosing spondylitis therapeutics market to 2019.

During the period 2000-2006, Celebrex, Enbrel, Remicade and Humira were approved for the treatment of ankylosing spondylitis. Increased uptake of these approved drugs resulted in the relatively high market growth witnessed throughout the period 2006-2011.

Ankylosing Spondylitis Market Has Moderate Unmet Need

The ankylosing spondylitis therapeutics market has moderate unmet need. The market is served by drug classes such as:
• Nonsteriodal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, indomethacin, diclofenac, Arcoxia (eterocoxib) and Celebrex
• Disease modifying anti-rheumatic drugs (DMARDs) including sulfasalazine, methotrexate
• Corticosteroids (prednisone)
• Biologics (Enbrel, Humira, Remicade, and Simponi)

These currently marketed drugs have moderate efficacy and safety profiles. The medications used either provide symptomatic relief or halt disease progression. This indicates that the market is in need of drugs that can cure the disease rather than providing symptomatic relief. Therefore, the ankylosing spondylitis therapeutics market is wide open for novel entrants with superior efficacy and safety to fulfill the existing unmet need.

Novartis
UCB

Customers who bought this item also bought

• Ankylosing Spondylitis (Bekhterev's Disease) Global Clinical Trials Review, H1, 2012
• Ankylosing Spondylitis: How Have Biological Therapies Affected the Market?
• Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H1 2013
• Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications
• United States Market for Ankylosing Spondylitis Pharmacotherapy
• Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2012
• Ankylosing Spondylitis: Surveyed Rheumatologists Await Non-TNF-Alpha Inhibitor Therapies in an Underserved Market
• Uncovering Biomarker and Diagnostic Opportunities in Immune and Inflammatory Diseases
• Rheumatology Thought Leader Panel #36 2012-08 Lupus / Rheumatoid Arthritis
• Special Report: The Pricing and Reimbursement Environment for Autoimmune Biologics